Silence Therapeutics PLC (LON:SLN)

Silence Therapeutics PLC (LON:SLN)


Share Price
69.00 p
Change
-1.5 (-2.13 %)
Market Cap
£49.79 m
Proactive Investors - Run By Investors For Investors

Silence Therapeutics PLC RNS Release

Silence Therapeutics appoints Head of R&D and CMO


RNS Number : 2649W
Silence Therapeutics PLC
16 April 2019
 

 

Silence Therapeutics appoints Giles Campion as Head of R&D and Chief Medical Officer

 

April 16, 2019

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Giles Campion, MD as Head of R&D and Chief Medical Officer, effective 1 June 2019.

 

An expert in translational medicine, Dr. Campion is a highly experienced biotech and pharmaceutical professional, bringing more than 20 years of experience in the industry. Most notably he served as Chief Medical Officer and Senior Vice President of R&D at Prosensa from 2009 to 2016, a European biotech company advancing oligonucleotide therapies for rare diseases, notably Duchenne muscular dystrophy (DMD). During this time the company signed a collaboration agreement with GSK worth up to $655 million with double digit royalties. Prosensa went on to list on Nasdaq in 2013, raising $90 million in an initial public offering nine times oversubscribed, and was ultimately acquired by Biomarin in 2015 for $680 million.

 

Previously, Giles held senior R&D roles at Novartis where he was a key member of a task force that defined the shape of a new integrated research organisation. Most recently, he served as Chief Medical Officer for Albumedix , Advisor to  Myotherix,  and a co-founder of PepGen, all companies focusing on therapies for rare diseases. At Albumedix his remit was to build a development portfolio based on the company's recombinant albumin platform and his work was instrumental in product development and an eventual financial exit for the owners of the company.  

 

Dr. Campion holds a medical degree and doctorate from Bristol University and is Board certified in rheumatology.

 

Commenting on the appointment, Dr. David Horn Solomon, Chief Executive Officer, said:

"On behalf of the Board of Silence Therapeutics, I am delighted to welcome Giles as the new Head of R&D and Chief Medical Officer. He has an outstanding track record of leading scientific development and advancing oligonucleotide-based medicines and is therefore ideally qualified to accelerate the development of our current and future pipeline. Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions."

 

Dr. Giles Campion, newly appointed Head of R&D and Chief Medical Officer of Silence Therapeutics, said:

"Silence Therapeutics is at the forefront of an extremely promising new class of RNA therapeutics and offers an exciting approach to tackling the unmet medical needs of patients suffering from serious diseases. I look forward to working with David and the management team as the Company looks to advance into the clinic in 2019 with the planned commencement of clinical trials for lead candidate SLN124 in Iron Overload Disorders including Beta Thalassemia."  

 

 

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

Dr Rob Quinn, Interim Chief Financial Officer

Tel:  +44 (0)20 3457 6900



Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAEAXLSFEFNEFF

Silence Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use